Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of MESA chemotherapy for extranodal NK/T-cell lymphoma
ChiCTR-PRNC-13003289Phase 2Completed
- Sponsor
- Department of Hematology, Xijing Hospital
- Start
- Aug 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, etoposide, dexamethasone and pegaspargase in extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Department of Hematology, Xijing Hospital. Primary endpoints: overall response rate and complete remission rate. Started Aug 2012; status: completed.
02
Drugs
methotrexateetoposidedexamethasonepegaspargase
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on ChiCTR-PRNC-13003289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-PRNC-13003289.